ArcticZymes Technologies launches SAN HQ 2.0 ELISA kit

20 Dec 2022 08:52 CET

Tromsø, Norway, 20[th] December 2022 - ArcticZymes Technologies ASA (OSE: AZT)
announces the launch of SAN HQ 2.0 ELISA kit

ArcticZymes Technologies (AZT) announces the launch of the SAN HQ 2.0 ELISA kit.

The SAN HQ 2.0 ELISA kit is intended as a natural companion product to our
already successful Salt Active Nuclease - SAN HQ 2.0. The new ELISA product is a
classic sandwich immunoassay designed to detect and quantify the presence of the
SAN HQ 2.0 nuclease at trace amounts.

Customers working with bioprocessing workflows will be able to use SAN HQ 2.0 to
remove contaminating nucleic acids, and then verify the removal of the nuclease
using the SAN HQ 2.0 ELISA kit after downstream processing and purification.

This is important as all processing agents, used during biomanufacturing
processes leading to human therapeutic agents, are subject to tight controls
with respect to residual amounts present in the final formulation.
Quantification is critical, therefore the enzyme SAN HQ 2.0 and the new SAN HQ
2.0 ELISA kit are complementary products. The new ELISA kit will further
accelerate the adoption of SAN HQ 2.0 in our customers' bioprocessing workflows.

The global biomanufacturing market has seen significant growth in recent years,
in part due to a boom in cell and gene therapy development, and the high demand
for vaccine manufacturing during the Coronavirus pandemic. Providing our
customers with more complete solutions, such as processing enzymes and
corresponding immunoassay kits, will be an important driver to continued sales
growth in the biomanufacturing business.

ArcticZymes Technologies ASA, CEO, Jethro Holter said:

"We are excited to announce the successful launch of the SAN HQ 2.0 ELISA kit.
It further extends the relevance of our SAN portfolio in the biomanufacturing
market."

For more information, please contact:

ArcticZymes Technologies
CEO, Jethro Holter Tel: +47 46 85 91 46
CFO, Børge Sørvoll Tel: +47 95 29 01 87
ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.

Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec]
ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies
in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at
the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large
portfolio of patents.

For more information, please visit the website: www.arcticzymes.com.

More information:
Access the news on Oslo Bors NewsWeb site

578689_AZT_SAN_HQ_2_0_ELISA_release_20122022.pdf